The hypothesis that cancer-specific antibody can be fused with anti-CD3 antibody to redirect T cell mediated killing effect in cancer patients have been supported by the approval of catumaxomab (anti-EpCAM and anti-CD3, [116]) and blinatumomab (anti-CD19 and anti-CD3, [117]). This evidence concerns the gene EPCAM and cancer.